ID: ALA333946

Max Phase: Preclinical

Molecular Formula: C14H16N5O4P

Molecular Weight: 349.29

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1nc(O)c2ncn(Cc3ccccc3CCP(=O)(O)O)c2n1

Standard InChI:  InChI=1S/C14H16N5O4P/c15-14-17-12-11(13(20)18-14)16-8-19(12)7-10-4-2-1-3-9(10)5-6-24(21,22)23/h1-4,8H,5-7H2,(H2,21,22,23)(H3,15,17,18,20)

Standard InChI Key:  HUKSVHVNPDSCKS-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 349.29

Molecular Weight (Monoisotopic): 349.0940

AlogP: 0.88

#Rotatable Bonds: 5

Polar Surface Area: 147.38

Molecular Species: ACID

HBA: 7

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 9

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 1.85

CX Basic pKa: 0.81

CX LogP: 0.38

CX LogD: -1.71

Aromatic Rings: 3

Heavy Atoms: 24

QED Weighted: 0.50

Np Likeness Score: -0.60

References

1. Kelley JL, Linn JA, McLean EW, Tuttle JV..  (1993)  9-[(Phosphonoalkyl)benzyl]guanines. Multisubstrate analogue inhibitors of human erythrocyte purine nucleoside phosphorylase.,  36  (22): [PMID:8230137] [10.1021/jm00074a029]

2. Erion MD, Niwas S, Rose JD, Ananthan S, Allen M, Secrist JA, Babu YS, Bugg CE, Guida WC, Ealick SE..  (1993)  Structure-based design of inhibitors of purine nucleoside phosphorylase. 3. 9-Arylmethyl derivatives of 9-deazaguanine substituted on the methylene group.,  36  (24): [PMID:8254607] [10.1021/jm00076a004]

Source

Source(1):

• Scientific Literature